Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;10(3):427-38.
doi: 10.1586/era.09.178.

Phase II Clinical Trials in Oncology: Are We Hitting the Target?

Affiliations
Review

Phase II Clinical Trials in Oncology: Are We Hitting the Target?

Mei-Kim Ang et al. Expert Rev Anticancer Ther. .

Abstract

The number of novel and molecularly targeted agents in the last decade that need screening for preliminary efficacy in Phase II trials has increased. Many of these agents have a cytostatic mode of action that is difficult to assess using traditional Phase II designs. These new agents require detailed evaluation to optimize their dosing, to evaluate their effects on their target and to define early markers that predict for a definitive benefit. This review focuses on the options for Phase II trial designs. The different end points, single versus multiarm and randomized designs, the use of biomarkers and Bayesian approaches are also reviewed. The final design chosen will depend on the characteristics and circumstances of each individual study.

Similar articles

See all similar articles

Cited by 3 articles

Publication types

MeSH terms

Feedback